Sign up
Pharma Capital

CytoDyn to begin proof-of-concept studies for leronlimab to treat liver damage caused by NASH

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors that the Cleveland Clinic will evaluate if its flagship drug leronlimab can prevent Non-Alcoholic Steatohepatitis (NASH), or "fatty liver" in mice.

Pourhassan says the Vancouver, Washington-based company will begin proof-of-concept studies of leronlimab in NASH in an 'expedited' fashion.

 

View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.